International Journal of Colorectal Disease

, Volume 22, Issue 2, pp 145–152 | Cite as

Microsatellite instability did not predict individual survival of unselected patients with colorectal cancer

  • C. Lamberti
  • S. Lundin
  • M. Bogdanow
  • C. Pagenstecher
  • N. Friedrichs
  • R Büttner
  • T. Sauerbruch
Original Article

Abstract

Introduction

High microsatellite instability (MSI-H) occurs in about 15% of colorectal cancers (CRC) and clinical as well as pathological features differ from tumours exhibiting low microsatellite instability (MSI-L) or microsatellite stability (MSS). Conflicting data exists about the relevance of MSI in predicting the prognosis and benefit of 5-fluorouracil (5-FU) based chemotherapy in patients with CRC. We investigated the usefulness of MSI as a predictor of distinct clinical attributes influencing recurrence rate and disease-free survival (DFS) subject to the use of adjuvant or palliative chemotherapy with 5-FU in stage II- stage IV CRC.

Methods

We collected data and tumours of 416 consecutive stage I to IV CRC patients from 2000 to 2002, and followed them for a median time of 33 months. Microsatellite loci recommended by the National Cancer Institute were analysed. Cox proportional hazard modelling was used to compare clinical data and survival as well as associations for MSI and 5-FU treatment status of patients with MSI-H, MSI-L or MSS CRC.

Results

We identified 52 MSI-H (13%), 21 MSI-L (5%) and 343 MSS (82%) tumours. CRC with MSI-H tended to have a decreased likelihood of metastasising to regional lymph nodes (p=0.055), whilst age of diagnosis and tumour location did not differ. In an analysis that did not take into account the use of chemotherapy, univariate and multivariate analyses failed to show a difference between MSI-H and MSS groups with respect to disease-free and overall survival. Furthermore, survival under application of 5-FU did not correlate with MSI status.

Conclusion

No clear influence of MSI status on overall survival and response to 5-FU chemotherapy was found.

Keywords

Colorectal cancer Microsatellite instability Prognosis Chemotherapy 

References

  1. 1.
    Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AM, Bos JL (1988) Genetic alterations during colorectal-tumor development. N Engl J Med 319:525–532PubMedCrossRefGoogle Scholar
  2. 2.
    Ionov Y, Peinado MA, Malkhosyan S, Shibata D, Perucho M (1993) Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature 363:558–561CrossRefPubMedGoogle Scholar
  3. 3.
    Aaltonen LA, Peltomaki P, Leach FS, Sistonen P, Pylkkanen L, Mecklin JP, Jarvinen H, Powell SM, Jen J, Hamilton SR et al (1993) Clues to the pathogenesis of familial colorectal cancer. Science 260:812–816PubMedCrossRefGoogle Scholar
  4. 4.
    Herman JG, Umar A, Polyak K, Graff JR, Ahuja N, Issa JP, Markowitz S, Willson JK, Hamilton SR, Kinzler KW, Kane MF, Kolodner RD, Vogelstein B, Kunkel TA, Baylin SB, Vertino PM (1998) Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Alterations in DNA methylation: a fundamental aspect of neoplasia. Proc Natl Acad Sci USA 95:6870–6875CrossRefPubMedGoogle Scholar
  5. 5.
    Veigl ML, Kasturi L, Olechnowicz J, Ma AH, Lutterbaugh JD, Periyasamy S, Li GM, Drummond J, Modrich PL, Sedwick WD, Markowitz SD (1998) Biallelic inactivation of hMLH1 by epigenetic gene silencing, a novel mechanism causing human MSI cancers. Proc Natl Acad Sci USA 95:8698–8702CrossRefPubMedGoogle Scholar
  6. 6.
    Thibodeau SN, Bren G, Schaid D (1993) Microsatellite instability in cancer of the proximal colon. Science 260:816–819PubMedCrossRefGoogle Scholar
  7. 7.
    Gryfe R, Kim H, Hsieh ET, Aronson MD, Holowaty EJ, Bull SB, Redston M, Gallinger S (2000) Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med 342:69–77CrossRefPubMedGoogle Scholar
  8. 8.
    Bubb VJ, Curtis LJ, Cunningham C, Dunlop MG, Carothers AD, Morris RG, White S, Bird CC, Wyllie AH (1996) Microsatellite instability and the role of hMSH2 in sporadic colorectal cancer. Oncogene 12:2641–2649PubMedGoogle Scholar
  9. 9.
    Brueckl W, Moesch C, Brabletz T, Koebnick C, Riedel C, Jung A, Merkel S, Schaber S, Boxberger F, Kirchner T, Hohenberger W, Hahn E, Wein A (2003) Relationship between microsatellite instability, response and survival in palliative patients with colorectal cancer undergoing first-line chemotherapy. Anticancer Res 23:1773–1777PubMedGoogle Scholar
  10. 10.
    Gafa R, Maestri I, Matteuzzi M, Santini A, Ferretti S, Cavazzini L, Lanza G, Calin GA, Tibiletti MG, Herlea V, Becheanu G, Barbanti-Brodano G, Nenci I, Negrini M, Dubini A, Gilli G (2000) Sporadic colorectal adenocarcinomas with high-frequency microsatellite instability. Cancer 89:2025–2037CrossRefPubMedGoogle Scholar
  11. 11.
    Garrity MM, Burgart LJ, Mahoney MR, Windschitl HE, Salim M, Wiesenfeld M, Krook JE, Michalak JC, Goldberg RM, O’Connell MJ, Furth AF, Sargent DJ, Murphy LM, Hill E, Riehle DL, Meyers CH, Witzig TE; NCCT Group (2004) Prognostic value of proliferation, apoptosis, defective DNA mismatch repair, and p53 overexpression in patients with resected Dukes’ B2 or C colon cancer: a North Central Cancer Treatment Group Study. J Clin Oncol 22:1572–1582CrossRefPubMedGoogle Scholar
  12. 12.
    Halling KC, French AJ, McDonnell SK, Burgart LJ, Schaid DJ, Peterson BJ, Moon-Tasson L, Mahoney MR, Sargent DJ, O’Connell MJ, Witzig TE, Farr GH Jr, Goldberg RM, Thibodeau SN (1999) Microsatellite instability and 8p allelic imbalance in stage B2 and C colorectal cancers. J Natl Cancer Inst 91:1295–1303CrossRefPubMedGoogle Scholar
  13. 13.
    Lothe RA, Peltomaki P, Meling GI, Aaltonen LA, Nystrom-Lahti M, Pylkkanen L, Heimdal K, Andersen TI, Moller P, Rognum TO et al (1993) Genomic instability in colorectal cancer: relationship to clinicopathological variables and family history. Cancer Res 53:5849–5852PubMedGoogle Scholar
  14. 14.
    Lukish JR, Muro K, DeNobile J, Katz R, Williams J, Cruess DF, Drucker W, Kirsch I, Hamilton SR (1998) Prognostic significance of DNA replication errors in young patients with colorectal cancer. Ann Surg 227:51–56CrossRefPubMedGoogle Scholar
  15. 15.
    Popat S, Hubner R, Houlston R (2005) Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 23:609–618CrossRefPubMedGoogle Scholar
  16. 16.
    Ribic C, Sargent D, Moore M, Thibodeau S, French A, Goldberg R, Hamilton S, Laurent-Puig P, Gryfe R, Shepherd L, Tu D, Redston M, Gallinger S (2003) Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 349:247–257CrossRefPubMedGoogle Scholar
  17. 17.
    Ward RL, Cheong K, Ku SL, Meagher A, O’Connor T, Hawkins NJ (2003) Adverse prognostic effect of methylation in colorectal cancer is reversed by microsatellite instability. J Clin Oncol 21:3729–3736CrossRefPubMedGoogle Scholar
  18. 18.
    Wright C, Dent O, Barker M, Newland R, Chapuis P, Bokey E, Young J, Leggett B, Jass J, Macdonald G (2000) Prognostic significance of extensive microsatellite instability in sporadic clinicopathological stage C colorectal cancer. Br J Surg 87:1197–1202CrossRefPubMedGoogle Scholar
  19. 19.
    Carethers JM, Smith EJ, Behling CA, Nguyen L, Tajima A, Doctolero RT, Cabrera BL, Goel A, Arnold CA, Miyai K, Boland CR (2004) Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer. Gastroenterology 126:394–401CrossRefPubMedGoogle Scholar
  20. 20.
    Curran B, Lenehan K, Mulcahy H, Tighe O, Bennett M, Kay E, O’Donoghue D, Leader M, Croke D (2000) Replication error phenotype, clinicopathological variables, and patient outcome in Dukes’ B stage II (T3,N0,M0) colorectal cancer. Gut 46:200–204CrossRefPubMedGoogle Scholar
  21. 21.
    Diep CB, Thorstensen L, Meling GI, Skovlund E, Rognum TO, Lothe RA (2003) Genetic tumor markers with prognostic impact in Dukes’ stages B and C colorectal cancer patients. J Clin Oncol 21:820–829CrossRefPubMedGoogle Scholar
  22. 22.
    Feeley KM, Fullard JF, Heneghan MA, Smith T, Maher M, Murphy RP, O’Gorman TA (1999) Microsatellite instability in sporadic colorectal carcinoma is not an indicator of prognosis. J Pathol 188:14–17CrossRefPubMedGoogle Scholar
  23. 23.
    Johannsdottir J, Bergthorsson J, Gretarsdottir S, Kristjansson A, Ragnarsson G, Jonasson J, Egilsson V, Ingvarsson S (1999) Replication error in colorectal carcinoma: association with loss of heterozygosity at mismatch repair loci and clinicopathological variables. Anticancer Res 19:1821–1826PubMedGoogle Scholar
  24. 24.
    Jover R, Zapater P, Castells A, Llor X, Andreu M, Cubiella J, Pinol V, Xicola.RM, Bujanda L, Rene JM, Clofent J, Bessa X, Morillas JD, Nicolas-Perez D, Paya A, Alenda C (2006) Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer. Gut 55(6):848–855Google Scholar
  25. 25.
    Ko JM, Cheung MH, Kwan MW, Wong CM, Lau KW, Tang CM, Lung ML (1999) Genomic instability and alterations in Apc, Mcc and Dcc in Hong Kong patients with colorectal carcinoma. Int J Cancer 84:404–409CrossRefPubMedGoogle Scholar
  26. 26.
    Messerini L, Ciantelli M, Baglioni S, Palomba A, Zampi G, Papi L (1999) Prognostic significance of microsatellite instability in sporadic mucinous colorectal cancers. Hum Pathol 30:629–634CrossRefPubMedGoogle Scholar
  27. 27.
    Salahshor S, Kressner U, Fischer H, Lindmark G, Glimelius B, Pahlman L, Lindblom A (1999) Microsatellite instability in sporadic colorectal cancer is not an independent prognostic factor. Br J Cancer 81:190–193CrossRefPubMedGoogle Scholar
  28. 28.
    Wang C, van Rijnsoever M, Grieu F, Bydder S, Elsaleh H, Joseph D, Harvey J, Iacopetta B (2003) Prognostic significance of microsatellite instability and Ki-ras mutation type in stage II colorectal cancer. Oncology 64:259–265CrossRefPubMedGoogle Scholar
  29. 29.
    Kim H, Jen J, Vogelstein B, Hamilton S (1994) Clinical and pathological characteristics of sporadic colorectal carcinomas with DNA replication errors in microsatellite sequences. Am J Pathol 148–156Google Scholar
  30. 30.
    Konishi M, Kikuchi-Yanoshita R, Tanaka K, Muraoka M, Onda A, Okumura Y, Kishi N, Iwama T, Mori T, Koike M, Ushio K, Chiba M, Nomizu S, Konishi F, Utsunomiya J, Miyaki M (1996) Molecular nature of colon tumours in hereditary nonpolyposis colon cancer, familial polyposis, and sporadic colon cancer. Gastroenterology 111:307–317CrossRefPubMedGoogle Scholar
  31. 31.
    Markowitz S, Wang J, Myeroff L, Parsons R, Sun L, Lutterbaugh J, Fan R, Zborowska E, Kinzler K, Vogelstein B et al (1995) Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science 268:1336–1338PubMedCrossRefGoogle Scholar
  32. 32.
    Morin P, Sparks A, Korinek V, Barker N, Clevers H, Vogelstein B, Kinzler KW (1997) Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 275:1787–1790CrossRefPubMedGoogle Scholar
  33. 33.
    Sparks A, Morin P, Vogelstein B, Kinzler K (1998) Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer. Cancer Res 58:1130–1134PubMedGoogle Scholar
  34. 34.
    Young J, Simms LA, Biden KG, Wynter C, Whitehall V, Karamatic R, George J, Goldblatt J, Walpole I, Robin SA, Borten MM, Stitz R, Searle J, McKeone D, Fraser L, Purdie D, Podger K, Price R, Buttenshaw R, Walsh MD, Barker M, Leggett BA, Jass JR (2001) Features of colorectal cancers with high-level microsatellite instability occurring in familial and sporadic settings: parallel pathways of tumorigenesis. Am J Pathol 159:2107–2116PubMedGoogle Scholar
  35. 35.
    Boland CR, Sinicrope FA, Brenner DE, Carethers JM (2000) Colorectal cancer prevention and treatment. Gastroenterology 118:115–128CrossRefPubMedGoogle Scholar
  36. 36.
    Laurie JA, Moertel CG, Fleming TR, Wieand HS, Leigh JE, Rubin J, McCormack GW, Gerstner JB, Krook JE, Malliard J, Poon MA, O’Connell MJ, Cullinan SA, Everson LK, Mailliard JA, Tschetter LK (1989) Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 7:1447–1456PubMedGoogle Scholar
  37. 37.
    Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Goodman PJ, Ungerleider JS, Emerson WA, Tormey DC, Glick JH et al (1990) Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 322:352–358PubMedCrossRefGoogle Scholar
  38. 38.
    Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Tangen CM, Ungerleider JS, Emerson WA, Tormey DC, Glick JH et al (1995) Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med 122:321–326PubMedGoogle Scholar
  39. 39.
    Aebi S, Fink D, Gordon R, Kim HK, Zheng H, Fink JL, Howell SB (1997) Resistance to cytotoxic drugs in DNA mismatch repair-deficient cells. Clin Cancer Res 3:1763–1767PubMedGoogle Scholar
  40. 40.
    Arnold CN, Goel A, Boland CR, Niedzwiecki D, Chang DK, Ricciardiello L, Carethers JM, Dowell JM, Wasserman L, Compton C, Mayer RJ, Bertagnolli MM (2003) Role of hMLH1 promoter hypermethylation in drug resistance to 5-fluorouracil in colorectal cancer cell lines. Characterization of sporadic colon cancer by patterns of genomic instability. Int J Cancer 106:66–73CrossRefPubMedGoogle Scholar
  41. 41.
    Carethers JM, Chauhan DP, Fink D, Nebel S, Bresalier RS, Howell SB, Boland CR (1999) Mismatch repair proficiency and in vitro response to 5-fluorouracil. Gastroenterology 117:123–131CrossRefPubMedGoogle Scholar
  42. 42.
    Carethers JM, Hawn MT, Chauhan DP, Luce MC, Marra G, Koi M, Boland CR (1996) Competency in mismatch repair prohibits clonal expansion of cancer cells treated with N-methyl-N′-nitro-N-nitrosoguanidine. J Clin Invest 98:199–206PubMedCrossRefGoogle Scholar
  43. 43.
    Hawn MT, Umar A, Carethers JM, Marra G, Kunkel TA, Boland CR, Koi M (1995) Evidence for a connection between the mismatch repair system and the G2 cell cycle checkpoint. Cancer Res 55:3721–3725PubMedGoogle Scholar
  44. 44.
    Elsaleh H, Iacopetta B, Powell B, McCaul K, Grieu F, Grant R, Joseph D, Shannon B (2001) Microsatellite instability is a predictive marker for survival benefit from adjuvant chemotherapy in a population-based series of stage III colorectal carcinoma. Clin Colorectal Cancer 1:104–109PubMedCrossRefGoogle Scholar
  45. 45.
    Hemminki A, Mecklin JP, Jarvinen H, Aaltonen LA, Joensuu H (2000) Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy. Gastroenterology 119:921–928CrossRefPubMedGoogle Scholar
  46. 46.
    Liang J, Huang K, Lai H, Lee P, Cheng Y, Hsu H, Cheng A, Hsu C, Yeh K, Wang S, Tang C, Chang K (2002) High-frequency microsatellite instability predicts better chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage IV sporadic colorectal cancer after palliative bowel resection. Int J Cancer 101:519–525PubMedCrossRefGoogle Scholar
  47. 47.
    Barratt PL, Seymour MT, Stenning SP, Georgiades I, Walker C, Birbeck K, Quirke P; Study. UKCCCR AXIS trial collaborators (2002) DNA markers predicting benefit from adjuvant fluorouracil in patients with colon cancer: a molecular study. Lancet 360:1381–1391CrossRefPubMedGoogle Scholar
  48. 48.
    Vasen HF, Mecklin JP, Khan PM, Lynch HT (1991) The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC). Dis Colon Rectum 34:424–425CrossRefPubMedGoogle Scholar
  49. 49.
    Vasen HF, Watson P, Mecklin JP, Lynch HT (1999) New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology 116:1453–1456CrossRefPubMedGoogle Scholar
  50. 50.
    Umar A, Boland CR, Terdiman JP, Syngal S, de la Chapelle A, Ruschoff J, Fishel R, Lindor NM, Burgart LJ, Hamelin R, Hamilton SR, Hiatt RA, Jass J, Lindblom A, Lynch HT, Peltomaki P, Ramsey SD, Rodriguez-Bigas MA, Vasen HF, Hawk ET, Barrett JC, Freedman AN, Srivastava S (2004) Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 96:261–268PubMedCrossRefGoogle Scholar
  51. 51.
    Kruse R, Rutten A, Schweiger N, Jakob E, Mathiak M, Propping P, Mangold E, Bisceglia M, Ruzicka T (2003) Frequency of microsatellite instability in unselected sebaceous gland neoplasias and hyperplasias. J Invest Dermatol 120:858–864CrossRefPubMedGoogle Scholar
  52. 52.
    Faivre-Finn C, Bouvier-Benhamiche AM, Phelip JM, Manfredi S, Dancourt V, Faivre J (2002) Colon cancer in France: evidence for improvement in management and survival. Gut 51:60–64CrossRefPubMedGoogle Scholar
  53. 53.
    Gatta G, Ciccolallo L, Capocaccia R, Coleman MP, Hakulinen T, Moller H, Berrino F (2003) Differences in colorectal cancer survival between European and US populations: the importance of sub-site and morphology. Eur J Cancer 39:2214–2222CrossRefPubMedGoogle Scholar
  54. 54.
    Sant M, Aareleid T, Berrino F, Bielska Lasota M, Carli PM, Faivre J, Grosclaude P, Hedelin G, Matsuda T, Moller H, Moller T, Verdecchia A, Capocaccia R, Gatta G, Micheli A, Santaquilani M, Roazzi P, Lisi D (2003) EUROCARE-3: survival of cancer patients diagnosed 1990–94—results and commentary. Ann Oncol 14:V61–V118CrossRefPubMedGoogle Scholar
  55. 55.
    Westra J, Schaapveld M, Hollema H, de Boer J, Kraak M, de Jong D, ter Elst A, Mulder N, Buys C, Hofstra R, Plukker J (2005) Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients. J Clin Oncol 23:5635–5643CrossRefPubMedGoogle Scholar
  56. 56.
    Tajima A, Hess M, Cabrera B, Kolodner R, Carethers J (2004) The mismatch repair complex hMutS alpha recognizes 5-fluorouracil-modified DNA: implications for chemosensitivity and resistance. Gastroenterology 127:1678–1684CrossRefPubMedGoogle Scholar
  57. 57.
    Elsaleh H, Joseph D, Grieu F, Zeps N, Spry N, Iacopetta B (2000) Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer. Lancet 355:1745–1750CrossRefPubMedGoogle Scholar
  58. 58.
    Carethers JM, Smith EJ, Behling CA, Nguyen L, Tajima A, Doctolero RT, Cabrera BL, Goel A, Arnold CA, Miyai K, Boland CR, Chauhan DP, Fink D, Nebel S, Bresalier RS, Howell SB (2004) Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer mismatch repair proficiency and in vitro response to 5-fluorouracil. Gastroenterology 126:394–401CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  • C. Lamberti
    • 1
  • S. Lundin
    • 1
  • M. Bogdanow
    • 3
  • C. Pagenstecher
    • 4
  • N. Friedrichs
    • 2
  • R Büttner
    • 2
  • T. Sauerbruch
    • 1
  1. 1.Department of Internal Medicine IUniversity of BonnBonnGermany
  2. 2.Department of PathologyUniversity of BonnBonnGermany
  3. 3.Department of Medical Biometrics, Informatics and EpidemiologyUniversity of BonnBonnGermany
  4. 4.Institute of Human GeneticsUniversity of BonnBonnGermany

Personalised recommendations